Back to top

Image: Bigstock

AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa

Read MoreHide Full Article

Key Takeaways

  • AstraZeneca wins US and EU approval for Klygefa to treat adults with AChR-positive gMG.
  • Phase III results showed significant daily activity improvements versus placebo after 26 weeks.
  • Weekly self-administration offers convenience but risks cannibalizing existing drugs and faces competition.

AstraZeneca (AZN - Free Report) announced that it has secured regulatory approvals in the United States and the European Union (EU) for Klygefa (gefurulimab), a new complement C5 inhibitor.

The FDA has approved Klygefa to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. In contrast, the drug has been approved in the EU as an add-on to standard therapy.

gMG is a rare autoimmune disorder marked by reduced muscle function and severe muscle weakness.

The approvals are supported by positive results from the phase III PREVAIL study, which showed that Klygefa significantly improved patients' ability to perform daily activities compared with placebo after 26 weeks. AstraZeneca noted that the improvements were observed as early as the first week of treatment.

The company estimates that approximately 98,500 people in the United States are diagnosed with gMG, of whom 81,000 are AChR antibody-positive. Across five major European countries — Germany, France, U.K., Italy and Spain — an estimated 82,500 people are diagnosed with the disease, including approximately 66,000 who are AChR antibody-positive.

AZN Stock Performance

Year to date, the company’s shares have gained 0.3% compared with the industry’s 8% growth.

Zacks Investment Research
Image Source: Zacks Investment Research

Klygefa Expands AstraZeneca's gMG Treatment Portfolio

The latest approvals further strengthen AstraZeneca's presence in the gMG treatment market by adding a once-weekly, self-administered subcutaneous (SC) therapy to its existing portfolio.

The company already markets two complement C5 inhibitors, Soliris and Ultomiris, for treating gMG. However, both treatments require intravenous (IV) infusions, with Soliris administered every two weeks and Ultomiris requiring maintenance infusions every eight weeks.

In contrast, Klygefa can be self-administered through a SC autoinjector once weekly, offering patients greater flexibility and convenience by reducing the need for regular visits to infusion centers. While this differentiated mode of administration could help AstraZeneca attract patients seeking more convenient treatment options, the drug could also cannibalize sales of Soliris and Ultomiris if patients switch from these existing therapies.

Despite its more convenient administration, Klygefa shares similar safety risks with AstraZeneca's existing C5 inhibitors. Like Soliris and Ultomiris, the newly approved drug carries a boxed warning for serious meningococcal infections in the United States. Consequently, Klygefa will be available in the country only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program.

Klygefa Faces Competition in the gMG Market

Beyond cannibalization concerns, AstraZeneca also competes with other drugmakers in the gMG treatment market.

A key competitor is UCB, which markets Zilbrysq, another complement C5 inhibitor approved for treating AChR antibody-positive gMG in adults. Like Klygefa, Zilbrysq can be self-administered through SC injections. However, Zilbrysq requires once-daily administration compared with Klygefa's once-weekly dosing, which could potentially give the latter a convenience advantage.

AstraZeneca also faces competition from drugs with different mechanisms of action. These include neonatal Fc receptor (FcRn) blockers, such as UCB's Rystiggo, argenx's (ARGX - Free Report) Vyvgart/Vyvgart Hytrulo and J&J's (JNJ - Free Report) Imaavy. Amgen (AMGN - Free Report) also markets Uplizna, a CD19-targeting B-cell therapy that offers twice-yearly maintenance dosing.

The availability of such alternative treatments could limit Klygefa's market share gains despite its convenient dosing schedule.

AZN’s Zacks Rank

AstraZeneca currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Published in